{"Symbol": "AMRN", "AssetType": "Common Stock", "Name": "Amarin Corporation PLC", "Description": "Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.", "CIK": "897448", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "DRUG MANUFACTURERS - GENERAL", "Address": "ONE CENTRAL PLAZA, DUBLIN, IRELAND, D02 K7K5", "OfficialSite": "https://www.amarincorp.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "306484000", "EBITDA": "-24665000", "PERatio": "None", "PEGRatio": "-1.74", "BookValue": "22.06", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-4.2", "RevenuePerShareTTM": "10.96", "ProfitMargin": "-0.38", "OperatingMarginTTM": "-0.0342", "ReturnOnAssetsTTM": "-0.0246", "ReturnOnEquityTTM": "-0.174", "RevenueTTM": "226733000", "GrossProfitTTM": "124606000", "DilutedEPSTTM": "-4.2", "QuarterlyEarningsGrowthYOY": "-0.942", "QuarterlyRevenueGrowthYOY": "0.174", "AnalystTargetPrice": "12", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "0", "AnalystRatingHold": "1", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "500", "PriceToSalesRatioTTM": "1.352", "PriceToBookRatio": "0.668", "EVToRevenue": "0.117", "EVToEBITDA": "-5.8", "Beta": "0.858", "52WeekHigh": "20.9", "52WeekLow": "7", "50DayMovingAverage": "14.77", "200DayMovingAverage": "15.05", "SharesOutstanding": "20792700", "SharesFloat": "375416000", "PercentInsiders": "1.964", "PercentInstitutions": "20.745", "DividendDate": "None", "ExDividendDate": "None"}